Niall Martin, Artios CEO
December 3, 2020 07:14 AM ESTUpdated 08:02 AM
Deals

Mer­ck KGaA bets big on DNA dam­age up­start, push­ing $30M up­front and hefty in­cen­tives for a Lyn­parza pi­o­neer

Jason Mast

Editor

The DNA dam­age spe­cial­ists over at Ar­tios Phar­ma have re­mained large­ly qui­et in the 2 1/2 years since their last fundraise, but what­ev­er they’ve been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times